Exonic

Exonic is pioneering a novel approach to drug discovery by establishing a global intelligence network focused on curing diseases. Departing from the traditional, insular model of pharmaceutical research conducted within secretive institutions, Exonic embraces openness and collaboration.

With the rise of biological AI, drug discovery is increasingly becoming a computational challenge. Exonic is transforming this process into an open, meritocratic competition, leveraging the collective intelligence of a global community.

Exonic's platform is advised by leading experts in bio AI, including the former Head of AI at Ginkgo Bioworks and the first author of Evo. By providing access to open-source biological AI models, Exonic empowers users to combine, prompt, and share innovative workflows without requiring coding expertise.

Exonic Studio has already demonstrated its capabilities by surpassing a state-of-the-art benchmark in liver cancer synthetic enhancer design, validated through wet lab experiments. The platform is now live, offering immediate access to its powerful tools and resources.

Exonic envisions a future where the internet becomes a driving force in drug discovery, accelerating the development of life-saving treatments.